Mitsubishi Tanabe   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Tokyo Japan (1999)

Organization Overview

First Clinical Trial
2001
NCT00129805
First Marketed Drug
2017
edaravone (radicava)
First NDA Approval
2017
edaravone (radicava)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Benesis Corporation | Information at Mitsubishi Tanabe Pharma Development America, Inc. | Mitsubihsi Tanabe Pharma Corporation | MITSUBISHI HOLDINGS | MITSUBISHI TANABE | Mitsubishi-Tanabe Pharma | Mitsubishi Tanabe Pharma America Inc. | Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Development America, Inc. | Mitsubishi Tanabe Pharma Europe Ltd | Mitsubishi Tanabe Pharma Europe Ltd. | Mitsubishi Tanabe Pharma GmbH | Mitsubishi-Tokyo Pharma | Tai Tien Pharmaceuticals Co., Ltd.